Advent Pharma Ltd. (DSE:ADVENT)
Bangladesh · Delayed Price · Currency is BDT 14.40
+0.20 (1.41%)
At close: Nov 12, 2026
Advent Pharma Balance Sheet
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.45 | 1.77 | 3.97 | 1.07 | 4.31 |
Cash & Short-Term Investments | 0.45 | 1.77 | 3.97 | 1.07 | 4.31 |
Cash Growth | -74.83% | -55.41% | 269.51% | -75.11% | -89.89% |
Receivables | 279.3 | 188.52 | 142.81 | 126.49 | 116.17 |
Inventory | 87.4 | 66.17 | 67.24 | 79.75 | 81.33 |
Prepaid Expenses | - | - | 0.05 | 0.05 | 0.05 |
Other Current Assets | 190.22 | 28.15 | 28.01 | 29.83 | 32.72 |
Total Current Assets | 557.37 | 284.61 | 242.08 | 237.2 | 234.59 |
Property, Plant & Equipment | 1,437 | 1,648 | 1,615 | 1,551 | 1,409 |
Total Assets | 1,994 | 1,932 | 1,857 | 1,788 | 1,644 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 9.9 | 10.08 | 9.64 | 20.6 | 10.42 |
Accrued Expenses | 59.64 | 47.49 | 43.87 | 61.51 | 48.74 |
Short-Term Debt | 59.81 | 58.67 | 60 | 54.99 | 43.27 |
Current Portion of Long-Term Debt | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 |
Current Portion of Leases | 0.17 | 0.7 | 0.67 | 0.76 | 0.64 |
Current Income Taxes Payable | 62.53 | 60.12 | 54.69 | 53.3 | 55.6 |
Other Current Liabilities | 5.16 | 3.9 | 12.1 | 7.24 | 2.99 |
Total Current Liabilities | 205.13 | 188.86 | 188.88 | 206.32 | 169.57 |
Long-Term Debt | 7.43 | 7.43 | 7.43 | 7.43 | 11.02 |
Long-Term Leases | 1.08 | 1.08 | - | 0.49 | 1.08 |
Long-Term Deferred Tax Liabilities | 214.23 | 204.4 | 190.41 | 175.2 | 148.56 |
Total Liabilities | 427.87 | 401.77 | 386.72 | 389.44 | 330.23 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 931.33 | 931.33 | 931.33 | 931.33 | 931.33 |
Retained Earnings | 634.68 | 599.04 | 538.68 | 467.73 | 382.12 |
Shareholders' Equity | 1,566 | 1,530 | 1,470 | 1,399 | 1,313 |
Total Liabilities & Equity | 1,994 | 1,932 | 1,857 | 1,788 | 1,644 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 76.41 | 75.79 | 76.01 | 71.59 | 63.92 |
Net Cash (Debt) | -75.97 | -74.03 | -72.04 | -70.52 | -59.61 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.82 | -0.79 | -0.77 | -0.76 | -0.64 |
Filing Date Shares Outstanding | 93.99 | 93.13 | 93.13 | 93.13 | 93.13 |
Total Common Shares Outstanding | 93.99 | 93.13 | 93.13 | 93.13 | 93.13 |
Working Capital | 352.24 | 95.75 | 53.2 | 30.88 | 65.02 |
Book Value Per Share | 16.66 | 16.43 | 15.78 | 15.02 | 14.10 |
Tangible Book Value | 1,566 | 1,530 | 1,470 | 1,399 | 1,313 |
Tangible Book Value Per Share | 16.66 | 16.43 | 15.78 | 15.02 | 14.10 |
Land | - | 3.78 | 3.78 | 3.78 | 3.78 |
Buildings | - | 1,245 | 1,245 | 1,245 | 1,123 |
Machinery | - | 570.15 | 530.34 | 527.92 | 458.43 |
Construction In Progress | - | 178.95 | 124.58 | 15.86 | 7.39 |